CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Rituximab 375 MG/M2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00856245
NCT00856245Phase 2Completed
CompareCT.gov

Role of Rituximab Containing Salvage Chemotherapy and in Vivo Purging in Obtaining PCR Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma or Transplant Eligible Mantle Cell Lymphoma

University of Kansas Medical Center·interventional·Posted Mar 5, 2009·Updated May 30, 2017

In Brief

A Phase 2 clinical trial evaluating Rituximab for Non-Hodgkins Lymphoma. Completed, enrolled 21 participants across 2 sites.

Detailed Summary

Researchers hope to learn if adding rituximab with high doses of chemotherapy and stem cell transplantation will help patients get rid of their lymphoma cells from the bone marrow and stem cell collections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkins Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 5, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 17.3 years ago

Interventions

Rituximabdrug

375 MG/M2 (milligram per meter squared) given IV (intravenously) weekly x 4-8 doses.